Related references
Note: Only part of the references are listed.Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
Lei Zha et al.
ADVANCES IN THERAPY (2020)
Outcomes and prognostic factors of tigecycline treatment for hospital-acquired pneumonia involving multidrug-resistant Acinetobacter baumannii
Ben Liu et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2020)
Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections
Gennaro De Pascale et al.
ANNALS OF INTENSIVE CARE (2020)
Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii
Yangang Zhou et al.
BMC PHARMACOLOGY & TOXICOLOGY (2019)
Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii
C. -A. Liang et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Synergy effect of meropenem- based combinations against Acinetobacter baumannii: a systematic review and meta-analysis
Zhihui Jiang et al.
INFECTION AND DRUG RESISTANCE (2018)
Dosing Guidance for Intravenous Colistin in Critically Ill Patients
Roger L. Nation et al.
CLINICAL INFECTIOUS DISEASES (2017)
Increasing Resistance to Extended-Spectrum Cephalosporins, Fluoroquinolone, and Carbapenem in Gram-Negative Bacilli and the Emergence of Carbapenem Non-Susceptibility in Klebsiella pneumoniae: Analysis of Korean Antimicrobial Resistance Monitoring System (KARMS) Data From 2013 to 2015
Dokyun Kim et al.
ANNALS OF LABORATORY MEDICINE (2017)
Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis
Wentao Ni et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
Mervyn Singer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients
Won-Young Kim et al.
PLOS ONE (2016)
Colistin for lung infection: an update
Mohan Gurjar
JOURNAL OF INTENSIVE CARE (2015)
In Vitro Assessment and Multicenter Cohort Study of Comparative Nephrotoxicity Rates Associated with Colistimethate versus Polymyxin B Therapy
Kady Phe et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems
George L. Daikos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis
Yu-Chung Chuang et al.
BMC INFECTIOUS DISEASES (2014)
High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria
Gennaro De Pascale et al.
CRITICAL CARE (2014)
Systematic Review and Meta-Analysis of In Vitro Synergy of Polymyxins and Carbapenems
Oren Zusman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Higher Incidence of Acute Kidney Injury With Intravenous Colistimethate Sodium Compared With Polymyxin B in Critically Ill Patients at a Tertiary Care Medical Center
Darowan S. Akajagbor et al.
CLINICAL INFECTIOUS DISEASES (2013)
High Prevalence of Multidrug-Resistant Nonfermenters in Hospital-acquired Pneumonia in Asia
Doo Ryeon Chung et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii
Jung-Jr Ye et al.
JOURNAL OF INFECTION (2011)
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia
Antonio T. Freire et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2010)
Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs
Jared L. Crandon et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections:: a review of the scientific evidence
Drosos E. Karageorgopoulos et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii
Jian Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Tigecycline: A critical analysis
Gary E. Stein et al.
CLINICAL INFECTIOUS DISEASES (2006)
In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004)
SK Bouchillon et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2005)
Guidelines for the management, of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia
[Anonymous]
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Share Paper
